Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: This release makes no mention of the costs of the drugs compared in this study, even though the drugs have been in use for years and are widely available. Since the study is a comparison of various treatments for this form of cancer, it seems relevant to offer a cost comparison as well as a comparison of efficacy. It appears that the high dose methotrexate is given over a 24-hour period, presumably in the hospital, while the standard methotrexate is given as a single dose. Also, the high dose methotrexate is followed by leucovorin administration while the standard dose is not. According to the site GoodRx, the cost for methotrexate in low-dose (2.5 mg) pill form averages out to about $50 for a month’s supply. Newer, injectable variations of the drug cost upwards of $500 a month for the 25 mg dose. The release states that patients receiving high doses of the drug methotrexate “had a significantly better outcome, by 5 to 6 percent” than did patients receiving the current standard of care, which is gradually escalating doses of the drug. The release also explains that patients nine years old or younger who were also treated with a steroid called decadron (dexamethasone) for half as long as normal (14 versus 28 days) benefited from the treatment while patients 10 and older did not. We’re not sure of the meaning behind these results as portrayed in the release. Which outcome was better by 5 or 6 percent? The study has several. Does that mean the relapse rate was reduced or is it the event free survival that was better? It would be more meaningful to readers if the release had included the actual relapse and event free survival rates for each group analyzed in terms most people can understand. For example: “relapse rates were 5 percent lower in Group X compared to Group Y.” We’ll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone “were at much higher risk for a debilitating bone condition called osteonecrosis,” although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well. The release stated the study was randomized and controlled, and provides a broad overview of the study design, for which we give the release a borderline satisfactory under this criteria. However, these are the superficial results. On deeper delving into the study methodology, the statistical significances of the results were very close to not statistically significant. This is due to their planned interim stopping of the treatment and the fact that they were looking at multiple outcomes in multiple groups. This release doesn’t demonstrate disease-mongering. While the release does say that this clinical trial was run by the Children’s Oncology Group, which is funded by the National Cancer Institute and the National Institutes of Health, it makes no mention of possible conflicts of interest. Compounding that is the fact that the published study says, “Disclosures provided by the authors are available with this article at www.jco.org,” but that information is behind the journal’s paywall for most readers, so it’s unknown if there is, or is not, a conflict. It appears as though five of the authors (out of a total of about 20) have some conflicts of interest, mostly from several types of drug company payments. The release is comparing the efficacy of treatment regimens using different drugs so alternative treatments for B-acute lymphoblastic leukemia are noted. The release makes clear at the end that the treatment of this disease is improving thanks to refinement of the use of existing drug treatments, meaning that they are readily available for patient use. The release suggests the study findings could change the way childhood leukemia is treated. Modifying existing treatments to enhance a patient’s survival is certainly novel enough to warrant a release. There is no use of unjustifiable language in this release. However, the tone may be a bit overly optimistic given the study findings.
Example Output: Relapses of childhood leukemia improve with high doses of common chemo drug

Example Input: According to two studies published on Wednesday, DNA from these pre-modern humans may play a role in the appearance of hair and skin as well as the risk of certain diseases. Although Neanderthals became extinct 28,000 years ago in Europe, as much as one-fifth of their DNA has survived in human genomes due to interbreeding tens of thousands of years ago, one of the studies found, although any one individual has only about 2 percent of caveman DNA. “The 2 percent of your Neanderthal DNA might be different than my 2 percent of Neanderthal DNA, and it’s found at different places in the genome,” said geneticist Joshua Akey, who led one of the studies. Put it all together in a study of hundreds of people, and “you can recover a substantial proportion of the Neanderthal genome.”  Both studies confirmed earlier findings that the genomes of east Asians harbor more Neanderthal DNA than those of Europeans. This could be 21 percent more, according to an analysis by Akey and Benjamin Vernot, published online in the journal Science. Still, “more” is a relative term. According to the paper by geneticists at Harvard Medical School, published in Nature, about 1.4 percent of the genomes of Han Chinese in Beijing and south China, as well as Japanese in Tokyo come from Neanderthals, compared to 1.1 percent of the genomes of Europeans. Anthropologists expressed caution about the findings. Fewer than half a dozen Neanderthal fossils have yielded genetic material, said Erik Trinkaus of Washington University in  St. Louis, one of the world’s leading experts on early humans. Using this small sample to infer how much Neanderthal DNA persists in today’s genome is therefore questionable, he said. As expected, since Neanderthals never existed in Africa, Africans and those who trace their ancestry to that continent have almost no Neanderthal DNA, the Harvard team found. Human ancestors began migrating out of humanity’s natal continent as early as 1 million years ago, paleoanthropologists infer from fossil evidence, and between 500,000 and 200,000 years ago evolved into the robust, large-browed Homo neanderthalensis in Western Europe. Ever since scientists extracted DNA from the remains of Neanderthals, they have known that people today carry snippets of cavemen genes, in the amounts of 2 percent to 3 percent. That clinched the case that Neanderthals and modern humans interbred, probably 40,000 to 80,000 years ago, soon after the latter arrived in Europe from Africa. The new studies add details about how much DNA and of what kind we inherited. “The story of early human evolution is captivating in itself, yet it also has far-reaching implications for understanding the organization of the modern human genome,” Irene Eckstrand of the National Institutes of Health’s National Institute of General Medical Sciences, which partially funded the research, said in a statement. “Every piece of this story that we uncover tells us more about our ancestors’ genetic contributions to modern human health and disease.”  The Harvard team used a novel genetic algorithm to estimate the probability that a particular genetic variant arose from Neanderthals. Basically, they started with the genome of a 50,000-year-old Neanderthal, and determined whether pieces of it also appeared in some non-Africans but not in sub-Saharan Africans. The algorithm identified remnants of Neanderthal DNA, called alleles, in genes associated with type 2 diabetes, Crohn’s disease, lupus, biliary cirrhosis and smoking behavior. “But we can’t tell if the Neanderthal alleles are contributing to disease,” said Harvard’s Sriram Sankararaman, lead author of the paper in Nature. Areas “with increased Neanderthal ancestry tend to be higher the farther away you go from genes,” sitting, instead, in regions of the genome that do not actually produce the proteins, enzymes and other working molecules of the body. Neanderthal DNA does sit within some genes, however, such as those for keratin, a fibrous protein that makes skin, hair and nails tough and can be beneficial in colder environments by providing thicker insulation. The endurance of this Neanderthal DNA suggests that our caveman inheritance was adaptive, picked by natural selection to persist in our genome, generation after generation, because it conferred a survival advantage in individuals who carried it. The Harvard team analyzed the genomes of 1,004 people to estimate which populations got more or fewer Neanderthal DNA. Confirming a 2013 study, they found more in the genomes of east Asians than in Europeans. But they also dug deeper. Puerto Ricans and Spaniards have the least Neanderthal DNA, 1.05 percent and 1.07 percent respectively. That is curious because Neanderthals made their last stand on the Iberian peninsula, finally dying out there 28,000 years ago. Across all populations, Neanderthal DNA is conspicuously low in regions of the X chromosome and in testes-specific genes. The paucity of Neanderthal genes among those active in the testes suggests that interbreeding wasn’t a resounding success: It produced viable children, but the males were infertile. Although as much as 20 percent of Neanderthal DNA persists in modern genomes, according to the Washington scientists, vast regions of the latter are Neanderthal deserts. Among them is a region of chromosome 7 that includes a gene called FOXP2. “FOXP2 has previously been implicated in speech and language and may be an example of a gene that influences a uniquely human trait, which is why we find no Neanderthal sequences in these regions,” said Akey.
Example Output: Modern humans more Neanderthal than once thought, studies suggest.

Example Input: Speaking to reporters aboard the plane returning to Rome from his trip to Asia, Francis renewed a call for a total ban on nuclear weapons, including their possession for the purpose of deterrence. Francis said declarations on the immorality of the use or possession of nuclear weapons would be incorporated in the Church’s universal catechism, a compilation of Catholic teachings and rules. The pope comforted victims of the 2011 Fukushima disaster on Monday in Tokyo and noted a call by Japan’s Catholic bishops to abolish nuclear power outright. Around 18,000 people died or were classified as missing after the so-called Triple Disaster, when a massive earthquake set off a tsunami - in some places 30 meters high - destroying a wide swathe of Japan’s northeastern coast and triggering a nuclear meltdown at the plant. “The use of nuclear energy is at the limit (of safety) because we still have not managed to achieve total security,” Francis said. “In my personal opinion, I would not use nuclear energy until there is total security. There is not enough security to guarantee that there will not be a disaster,” Francis added. Francis said assertions that nuclear accidents were rare were insufficient because effects of radiation are felt for decades on people and the environment, such as in the area around the Chernobyl reactor in Ukraine which was crippled by a meltdown in 1986. Francis, who wrote a major encyclical in 2015 on protection of the environment and the effects of global warming, said humanity had gone beyond the limit in violating nature. As examples, he listed the overuse of pesticides and dispensing growth hormones to animals destined for human consumption. “The (need for the) protection of the environment has gotten to the point where it is either now or never,” he said. Without naming countries, Francis accused states of practicing ‘armament hypocrisy’, saying nations of Christian tradition “speak of peace but live off weapons. This is called hypocrisy”. Francis said the United Nations does much good around the world but criticized the system that gives veto power to only a few nations in the Security Council. “Without meaning any offence to anyone, think of the (UN) Security Council: if here is a problem with weapons and everybody votes in favor of avoiding a bellicose action ... and one with veto power votes no, everything stops,” he said. The Security Council has five permanent members with veto power - the United States, Russia, Britain, France and China. “I have heard people say that the United Nations should move forward and give up the right of veto of some nations ... It would be beautiful if everyone had the same right,” Francis said.
Example Output:
Nuclear energy needs greater safety guarantees, pope says.